0.64
+1.59%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Advicenne
Its shares trade on Euronext Paris under the ticker ALDVI.PA. It has been listed since 6 December 2017. In the fiscal year to 31 December 2025, it reported revenue of €6.0m and a net loss of €9.5m. At that date it held total assets of €7.1m and shareholders' equity of −€26.4m.
Advicenne SA develops and markets pediatric drugs for the treatment of neurological diseases. The company is headquartered in Nimes, Occitanie. The company went IPO on 2017-12-06. The firm focuses on the development of paediatric friendly therapeutics for the treatment of orphan renal diseases and niche neurology indications. The Company’s medicines are developed for patients of all ages in the fields of nephrology and neurology. Its lead product includes ADV7103, which is in phase III, designed to address dRTA both in children for whom the disease is genetic as well as for adults who may have acquired the condition as a result of autoimmune disease. Apart from its lead product, the Company also develops a portfolio of products, including ADV6209, which is an oral liquid solution for moderate sedation; Likozam, which is designed to meet the unmet medical need of patients with partial and generalized chronic refractory epilepsy; Levidcen, which is used to address the unmet medical need of epileptic patients with partial onset seizures, and ADV7103 Cystinuria, among others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 6 Dec 2017
- Employees
- 32
- Website
- advicenne.com ↗
Leadership
Pay as last reported
- M.L. Philippe BoucheronChairman of the Board, since 2011
- Mr. Didier LaurensChief Executive Officer, Executive Director, since 2021€212,899
- Mr. Laurent CassedanneDeputy Chief Executive Officer and Head Pharmacist€153,567
- Mr. Thibaut RoulonPermanent Representative of BPI France Investissement, since 2011
- Mrs. Catherine DunandDirector, Permanent Representative of Cemag Invest
- Ms. Charlotte SibleyIndependent Director€106,800
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Advicenne SA develops and commercializes innovative pharmaceutical products for rare kidney and neurological diseases. Their unique formulations and solutions cater to unmet medical needs, providing a competitive advantage in the market.
- The company invests significantly in research and development, focusing on advanced drug delivery systems and addressing rare diseases. This commitment enhances their product pipeline, potential collaborations, and growth opportunities.
Weaknesses
- Advicenne's market penetration is currently limited, primarily due to their focus on rare diseases. This narrow target audience poses challenges for scaling up sales and generating substantial revenue compared to companies targeting larger patient populations.
- As a pharmaceutical company, Advicenne's success heavily relies on obtaining regulatory approvals for their products. Delays or rejections in the approval process can adversely impact their business and growth prospects.
Opportunities
- The global rare disease market is growing, presenting an opportunity for Advicenne to expand its market reach. With continued advancements in healthcare and increased awareness of rare diseases, the company can leverage its expertise to capture a larger share of this market.
- Advicenne can explore strategic partnerships with pharmaceutical companies, research institutions, and healthcare organizations. Collaborations can enhance their research capabilities, product development, distribution networks, and market presence.
Threats
- The pharmaceutical industry is highly competitive, with many established players and emerging biotech companies entering the market. Advicenne may face fierce competition in terms of innovative solutions, pricing, and market access.
- Regulatory and legal constraints can pose challenges to Advicenne's operations. Adherence to strict regulations, patent protection, and intellectual property rights are crucial for maintaining a competitive edge and protecting their products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.